Literature DB >> 2459829

In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts.

A J Beniers1, W P Peelen, B T Hendriks, J A Schalken, J C Romijn, F M Debruyne.   

Abstract

The in vitro antitumor activity of recombinant alpha- and gamma-Interferon as well as recombinant Tumor Necrosis Factor alpha was tested on renal cell carcinoma xenografts using the double layer soft agar method. Using this assay, the effect of the drugs on the clonogenic potential of tumor cells in soft agar was determined and used as an indication for the antiproliferative capacity of these drugs. There appeared to be a differential response of the tested xenografts towards these drugs in a dose dependent way. However, when used in combination in most cases an additive or synergistic effect was observed. Even though again the response was differential, the combination of alpha-Interferon (10 ng/dish) and Tumor Necrosis Factor (100 ng/dish) resulted in a complete inhibition of colony formation in soft agar for both tumor lines. We conclude that there is a direct effect of alpha-Interferon, gamma-Interferon and Tumor Necrosis Factor on renal cell carcinoma xenografts. In combination drug tests the effect of alpha-Interferon and Tumor Necrosis Factor was strongly synergistic. The implication of these studies for in vivo use of these drugs remain to be established.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459829     DOI: 10.1007/bf00263641

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  48 in total

1.  Synergistic interaction of anticancer agents: a cellular perspective.

Authors:  F Valeriote; H s Lin
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

Authors:  P G Brouckaert; G G Leroux-Roels; Y Guisez; J Tavernier; W Fiers
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

3.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines.

Authors:  L Fransen; J Van der Heyden; R Ruysschaert; W Fiers
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

4.  Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells.

Authors:  T Murase; T Hotta; H Saito; R Ohno
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

5.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

6.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

7.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

8.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

9.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells.

Authors:  M Tsujimoto; Y K Yip; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  7 in total

1.  Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft.

Authors:  G O Oosterhof; G A Smiths; J E deRuyter; J A Schalken; F M Debruyne
Journal:  Urol Res       Date:  1990

2.  Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.

Authors:  P H de Mulder; F M Debruyne; M P Franssen; A D Geboers; S Strijk; A G Reintjes; W H Doesburg; O Damsma
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.

Authors:  S A Kadhim; J L Chin
Journal:  Urol Res       Date:  1991

4.  Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Authors:  J T Donaldson; T E Keane; S H Poulton; P J Walther
Journal:  Urol Res       Date:  1990

5.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

6.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

Review 7.  Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

Authors:  M M Walther; S B Jennings; P L Choyke; M Andrich; K Hurley; W M Linehan; S A Rosenberg; R B Alexander
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.